3.4 Toxicities
Common late adverse effects were mainly skin/mucosal toxicities. There were 2 cases of late severe adverse effects (6.5%), including one case of grade 4 mandibular osteonecrosis and one case of grade 3 skin/mucosal toxicity. The patient suffered from mandibular osteonecrosis had received two courses of EBRT before last recurrence, of which the total dose accumulated to 138Gy. Another patient suffered from grade 3 skin/mucosal toxicity had received one course of EBRT for a total dose of 70Gy. Besides, eleven patients (41.9%) suffered from late grade 1-2 adverse effects, including ten cases (32.2%) of skin/mucosal toxicities and one case (3.2%) of pain.